Y-Intercept (HK)’s Pacira BioSciences PCRX Stock Holding History

Y-Intercept (HK)’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,302	Closed	-$575K	–	1890
2025 Q3	$575K	Buy	22,302 +10,306	+86%	+$253K	0.01%	1222
2025 Q2	$287K	Buy	+11,996	New	+$302K	0.01%	1373
2023 Q2	–	Sell	-7,731	Closed	-$316K	–	1612
2023 Q1	$316K	Sell	7,731 -7,340	-49%	-$292K	0.04%	747
2022 Q4	$582K	Buy	+15,071	New	+$733K	0.09%	380

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Y-Intercept (HK)'s PCRX Position: Q4 2025 in Review

Y-Intercept (HK) sold out of Pacira BioSciences (PCRX) in Q4 2025, closing a stake of 22,302 shares — an estimated $575K sold.

Y-Intercept (HK) first reported a position in PCRX in Q4 2022 and held it in 4 quarters. The position peaked at $582K in Q4 2022. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

Y-Intercept (HK) reported no remaining Pacira BioSciences position as of Q4 2025 after selling out during the quarter.
Y-Intercept (HK) sold 22,302 Pacira BioSciences shares in Q4 2025, an estimated $575K.
Y-Intercept (HK) first reported a position in Pacira BioSciences in Q4 2022 and held it in 4 quarters.
Y-Intercept (HK)'s Pacira BioSciences position peaked at $582K in Q4 2022.
260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Y-Intercept (HK)'s 13F filing for Q4 2025, filed 13 Feb 2026.